News CRISPR Therapeutics plans Nasdaq launch CRISPR Therapeutics, the Swiss genome-editing company, has filed for a $90 million initial public offering.
Articles Never mind the chill, biotech IPO winter will pass After two giddy years of continuous growth, biotech got a rude awakening in late 2015, but many remain confident in the sector's growth potential, writes Andrew McConaghie.
News Circassia leads UK biotech funding success Three separate fund-raising rounds - headed by Circassia's £275 million placing and open offer - give a further indication of the revival in the
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
